• Fate Therapeutics established an at-the-market offering program of up to $100 million in common stock on November 5, 2026.
• Leerink Partners will act as sales agent, earning commissions of up to 3% of gross proceeds.
• The company terminated its previous $100 million at-the-market sales agreement with Jefferies the same day, without termination penalties.
• Sales under the Jefferies agreement totaled 2,801,602 shares, generating $8 million in gross proceeds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-449840), on November 05, 2026, and is solely responsible for the information contained therein.